The EPS projection of Core Laboratories N.V. (NYSE:CLB) for quarter ended 2016-09-30 is $0.37. Last week, the EPS forecast was $0.37 against target of $0.37, a month earlier. Two months ago, this estimate was $0.37 versus forecast of $0.37 three months earlier, implying a deviation of 0%.
Core Laboratories N.V. (NYSE:CLB) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 2.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 0, and 1, correspondingly.
EPS estimate downgrade for Core Laboratories N.V. (NYSE:CLB) in the preceding 30, 120, 60 and 90 days were 0, 3, 1, and 2, correspondingly.
Core Laboratories N.V. (NYSE:CLB) EPS target for the quarter closed 1 was $0.37, based on 5 recommendations. As reported on 2016-04-20 the EPS was $0.37. The change was $0, implying a percentage deviation of 0%. The projections showed a standard deviation of 0.02.
Quarterly Sales Estimates
Core Laboratories N.V. (NYSE:CLB) yearly sales prediction for the fiscal 2017 stands at $160.1 and the median estimate is at $160.1. Almost 2 analysts issued sales target.
Highest sales target is $161.6 while the lowest target is $158.6 showing standard deviation of 2.121%.
As many as 2 analysts have sales targets revised upside while 2 reduced sales estimates, implying a deviation of 0%.
Last month, 2 revised sales number projection on upside while 2 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast. Core Laboratories N.V. (NYSE:CLB) announced that the deviation in forecast was -3.814%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...